Introduction
obesity, antipsychotic-induced weight gain, weight gain, schizoaffective disorder, Schizophrenia, schizophrenia, psychotic mental disease
OBESITY
Schizophrenia is a chronic, psychotic mental disease that affects approximately one percent of people. The time of onset is typically in late adolescence or early adulthood and regularly continues through the whole life (Freedman Pharmacological treatment was introduced more than half a century ago with the discovery of DOne of the leading causative genes regarding weight gain itself is A GWAS conducted later reported 20 SNPs near the So far, few studies have investigated the influence of the rs17782313 polymorphism on antipsychotic-induced weight gain and produced not entirely consistent results. Czerwensky et al. (After more than a decade since the discovery of rs17782313 as a strong mediator in obesity and nearly 10 years since the first investigation of its influence in AIWG, there remains a need for more studies to clarify the effect it has on SGA-related weight gain and create a basis for future meta-analyses on this matter. Thus, we investigated the influence of rs17782313 on weight gain in 252 patients that took part in a multicenter randomized, controlled, double-blind study comparing two treatment strategies for acute schizophrenia or schizoaffective disorder.